MSFT   185.07 (+0.09%)
FB   230.16 (-1.10%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
BABA   218.57 (+1.98%)
MU   48.92 (+4.49%)
GE   7.26 (+2.98%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.50 (+1.65%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.20 (+2.91%)
NFLX   421.97 (-1.25%)
BAC   25.97 (+4.55%)
BA   173.07 (+12.89%)
MSFT   185.07 (+0.09%)
FB   230.16 (-1.10%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
BABA   218.57 (+1.98%)
MU   48.92 (+4.49%)
GE   7.26 (+2.98%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.50 (+1.65%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.20 (+2.91%)
NFLX   421.97 (-1.25%)
BAC   25.97 (+4.55%)
BA   173.07 (+12.89%)
MSFT   185.07 (+0.09%)
FB   230.16 (-1.10%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
BABA   218.57 (+1.98%)
MU   48.92 (+4.49%)
GE   7.26 (+2.98%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.50 (+1.65%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.20 (+2.91%)
NFLX   421.97 (-1.25%)
BAC   25.97 (+4.55%)
BA   173.07 (+12.89%)
MSFT   185.07 (+0.09%)
FB   230.16 (-1.10%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
BABA   218.57 (+1.98%)
MU   48.92 (+4.49%)
GE   7.26 (+2.98%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.50 (+1.65%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.20 (+2.91%)
NFLX   421.97 (-1.25%)
BAC   25.97 (+4.55%)
BA   173.07 (+12.89%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 AllerganVertex PharmaceuticalsBayerZoetisRegeneron Pharmaceuticals
SymbolNYSE:AGNNASDAQ:VRTXOTCMKTS:BAYRYNYSE:ZTSNASDAQ:REGN
Price Information
Current Price$193.02$276.92$17.93$142.53$604.28
52 Week RangeHoldBuyBuyBuyBuy
Beat the Market™ Rank
Overall Score1.91.41.52.31.4
Analysis Score1.02.40.02.32.3
Community Score3.33.22.33.22.6
Dividend Score3.30.03.34.20.0
Ownership Score1.01.00.01.01.0
Earnings & Valuation Score0.60.61.90.61.3
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$186.71$278.81N/A$141.50$551.07
% Upside from Price Target-3.27% downside0.68% upsideN/A-0.72% downside-8.80% downside
Trade Information
Market Cap$63.50 billion$74.32 billion$66.88 billion$67.47 billion$65.95 billion
Beta1.20.951.220.790.57
Average Volume4,008,5761,941,448638,6862,200,1661,982,693
Sales & Book Value
Annual Revenue$16.09 billion$4.16 billion$48.23 billion$6.26 billion$7.86 billion
Price / Sales3.9517.251.3910.818.45
Cashflow$36.70 per share$4.60 per share$3.57 per share$4.69 per share$24.42 per share
Price / Cash5.2660.155.0230.4124.75
Book Value$177.28 per share$23.66 per share$14.27 per share$5.69 per share$100.56 per share
Price / Book1.0911.701.2625.056.01
Profitability
Net Income$-5,271,000,000.00$1.18 billion$4.58 billion$1.50 billion$2.12 billion
EPS$17.64$4.29$1.77$3.64$21.47
Trailing P/E RatioN/A47.9914.5842.5530.37
Forward P/E Ratio10.6532.058.3035.9019.15
P/E Growth$1.63$1.39$1.28$4.92$1.28
Net Margins-15.44%31.35%9.65%25.41%28.56%
Return on Equity (ROE)8.46%25.69%14.15%67.72%24.94%
Return on Assets (ROA)5.31%18.50%5.09%15.76%18.81%
Dividend
Annual Payout$2.96N/A$0.53$0.80N/A
Dividend Yield1.53%N/A2.96%0.56%N/A
Three-Year Dividend Growth428.57%N/AN/AN/AN/A
Payout Ratio16.78%N/A29.94%21.98%N/A
Years of Consecutive Dividend Growth2 YearsN/AN/A6 YearsN/A
Debt
Debt-to-Equity Ratio0.31%0.08%0.78%2.22%0.06%
Current Ratio1.01%3.54%1.40%2.77%4.21%
Quick Ratio0.84%3.42%0.94%1.91%3.49%
Ownership Information
Institutional Ownership Percentage83.91%93.40%0.12%91.45%68.04%
Insider Ownership Percentage0.08%0.48%N/A0.17%11.28%
Miscellaneous
Employees17,4003,000103,82410,6008,100
Shares Outstanding329.00 million259.28 million3.73 billion474.94 million110.02 million
Next Earnings Date8/4/2020 (Estimated)7/29/2020 (Estimated)8/4/2020 (Estimated)8/4/2020 (Estimated)8/4/2020 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.